239 Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis

Thomas Gajewski, Emily Higgs, Shuyin Li, Blake Flood, Ken Hatogai
2020 Journal for ImmunoTherapy of Cancer  
BackgroundCheckpoint blockade therapies have transformed the landscape of cancer care. Durable clinical responses have been observed in a subset of patients. However, many patients do not respond, and understanding the mechanisms that determine tumor resistant to checkpoint blockade drugs could potentially benefit more patients. Ferroptosis is a relatively newly described form of regulated cell death distinct from apoptosis and necroptosis. Recently, T cell-promoted tumor ferroptosis was shown
more » ... roptosis was shown to be an anti-tumor mechanism and targeting this pathway could be a potential therapeutic approach.MethodsTo identify genes critical to immunotherapy resistance, B16.SIY cells were transduced with a genome-scale gRNA lentivirus to generate loss of function mutants. In vitro-primed CD8+ T cells isolated from 2C/Rag2–/– TCR transgenic mice specific for the SIY antigen were co-cultured with transduced B16.SIY tumor cells. Resistant mutants were identified by sequencing the gRNAs of survival clones. The gene encoding Decr2, a peroxisomal 2,4-dienoyl-CoA reductase, was identified. To investigate the role of Decr2 in tumor growth and immune responses in vivo, the Decr2 knock-down or Decr2 overexpressed tumors were transplanted into B6 mice and the mice were subsequently treated with anti-PD-L1 antibody. The tumor microenvironments were analyzed by flow cytometry. To understand the resistance mechanism of Decr2 knock-down tumors, RNA-seq was performed and analyzed. The CD8+ T cell mediated tumor ferroptosis in vitro and in vivo was analyzed for lipid reactive oxygen species.ResultsDecr2 mutants were relatively resistant to CD8+ T cell killing in vitro. Consistent with this resistance to CD8+ T cell killing, Decr2 knock-down tumors showed minimal response to anti-PDL1 therapy in vivo. RNA-seq analysis of Decr2 knock-down B16.SIY tumors revealed upregulation of ferroptosis-related genes, including slc7a11. Further mechanistic studies showed that Decr2 knock-down tumors displayed defects in ferroptosis in vitro and in vivo.ConclusionsDecr2-deficient tumors were relatively resistant to CD8+ T cell killing in vitro and anti-PD-L1 immunotherapy in vivo by modulating CD8+ T cell-induced ferroptosis.
doi:10.1136/jitc-2020-sitc2020.0239 fatcat:p4fnq6w2xbgyhhyrd52upvoaci